Semaglutide is approved for long-term, ongoing use with no set end date. The FDA specifically labeled Wegovy (the weight management version) for “chronic weight management,” meaning it’s designed to be taken indefinitely, much like medications for high blood pressure or cholesterol. Clinical trials have now tracked people taking it continuously for up to four years, showing sustained weight loss and cardiovascular benefits throughout that period.
That said, “you can take it indefinitely” and “you should take it indefinitely” aren’t the same thing. The practical answer depends on your goals, your body’s response, your side effects, and whether you can keep accessing it.
Why It’s Considered a Long-Term Medication
Major medical organizations treat obesity as a chronic, relapsing condition, similar to diabetes or hypertension. The American Association of Clinical Endocrinology and the American Diabetes Association both emphasize that many patients need long-term drug therapy, not short courses. The World Health Organization issued global guidance in 2025 recommending that GLP-1 medications like semaglutide “may be used by adults for the long-term treatment of obesity,” though they noted the recommendation is conditional because data on very long-term safety (beyond four to five years) is still limited.
The longest published clinical data comes from an extension of the SELECT cardiovascular trial, which followed participants for an average of about 40 months (just over three years). A separate analysis presented by the European Association for the Study of Obesity showed that weight loss continued through the first 65 weeks and was sustained for four full years of continuous treatment. No new safety signals emerged during that time.
What Happens When You Stop
This is the finding that convinces most doctors to keep patients on the medication. A 2026 meta-analysis published in The Lancet mapped the trajectory of weight regain after stopping GLP-1 medications and found a clear pattern: within one year of stopping, people regained about 60% of the weight they had lost during treatment. The researchers projected that regain eventually plateaus at roughly 75% of lost weight.
So if you lost 40 pounds on semaglutide and then stopped, you could expect to regain about 24 pounds within a year, and potentially 30 pounds over the longer term. The weight doesn’t come back because of a lack of willpower. Semaglutide works by suppressing appetite signals in the brain and slowing digestion. When you remove the drug, those biological drives return to their previous levels.
The Titration Phase and Maintenance Dosing
Before you settle into long-term use, there’s a ramp-up period. For Ozempic (used for type 2 diabetes), the starting dose is 0.25 mg once weekly for the first four weeks, increasing to 0.5 mg at week five, with a maximum dose of 2 mg. Wegovy follows a similar escalation over about 16 to 20 weeks before reaching the full 2.4 mg maintenance dose.
This gradual increase exists to reduce gastrointestinal side effects like nausea and vomiting, which are most common during the early weeks. Once you reach your maintenance dose, that’s typically where you stay for as long as you continue treatment. Some people work with their prescriber to find a lower dose that controls their weight with fewer side effects, but there’s no standard protocol for dose reduction. Guidelines from major medical organizations don’t include formal tapering recommendations. Instead, decisions about adjusting the dose are individualized, based on factors like weight trends (whether you regain more than 2%), hunger levels, and metabolic markers.
When Doctors Consider Stopping Treatment
There are no universal clinical criteria for discontinuing semaglutide, but a few scenarios commonly lead to stopping. The most straightforward is intolerable side effects, particularly persistent nausea, vomiting, or abdominal pain that doesn’t improve after the titration period. Some patients also choose to stop after reaching a target weight, though the regain data suggests this often leads to a return visit.
Certain medical conditions rule out continued use entirely. People with a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma, or a condition called multiple endocrine neoplasia syndrome type 2, should not take semaglutide. The drug carries a boxed warning about thyroid tumor risk based on animal studies. Pancreatitis is another red flag. While it’s uncommon, semaglutide can trigger or worsen inflammation of the pancreas, and a history of pancreatitis means closer monitoring or discontinuation.
Long-Term Safety Considerations
The cardiovascular data is actually encouraging for long-term users. The SELECT trial, which followed patients for an average of nearly 40 months, found that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20%. This is one of the strongest arguments for continued use in people with both excess weight and cardiovascular risk.
The concerns that remain are largely about unknowns. Four years of clinical trial data is reassuring but not the same as 10 or 20 years of real-world evidence. The thyroid tumor warning is based on rodent studies and hasn’t been confirmed in humans, but it hasn’t been ruled out over very long time horizons either. Gastrointestinal issues, the most common side effects, tend to be worst during the dose escalation phase and improve with time, which is actually a point in favor of long-term use over repeated start-stop cycles.
Insurance Coverage Can Limit Duration
Even if the medical case supports indefinite use, insurance coverage often creates practical time limits. A review of U.S. commercial health plans found that approval periods for semaglutide varied enormously, from as short as 12 weeks to as long as two years. After that initial window, every plan that reported continuation criteria required documented weight loss, typically at least 4% to 5% from baseline, to authorize ongoing refills. Two plans also required that the patient’s BMI had dropped to 25 or below.
This means your ability to stay on semaglutide long-term may depend as much on your insurer’s policies as on your doctor’s recommendation. If coverage lapses, the cost of paying out of pocket for a brand-name GLP-1 medication is substantial, which is one of the most common reasons people discontinue treatment in real-world settings. Gaps in clinic visits or prescription refills of more than 12 consecutive weeks are typically considered a discontinuation in clinical practice, which can complicate reauthorization.
Staying On vs. Cycling Off
Some people wonder whether they can take semaglutide for a defined period, stop, and restart later if the weight returns. This is technically possible, and many patients do follow this pattern in practice. But it’s not the approach clinical evidence supports. The weight regain curve is steep and predictable, and restarting means going through the titration phase again, with its associated side effects.
The current medical consensus is straightforward: if semaglutide is working, you’re tolerating it well, and you can access it, continuing treatment is preferable to cycling on and off. The WHO, the American medical associations, and the prescribing labels all point in the same direction. This is a chronic medication for a chronic condition, and the evidence available so far, up to four years, supports that approach.